Cresco Labs (CRLBF) Cash from Investing Activities (2019 - 2025)
Cresco Labs' (CRLBF) quarterly Cash from Investing Activities came in at -$13.2 million in Q4 2025, down 339.5% YoY from $5.5 million in Q4 2024, and down 116.23% on a QoQ basis from -$6.1 million in Q3 2025.
Cresco Labs (CRLBF) Cash from Investing Activities (2019 - 2025) Analysis & Trends
Cresco Labs (CRLBF) has 7 years of Cash from Investing Activities data on file, last reported at -$13.2 million in Q4 2025.
- Quarterly Cash from Investing Activities fell 339.5% year-over-year to -$13.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$28.6 million (down 49.61% YoY) and the FY2025 annual result came in at -$40.7 million, down 61.34% from the prior year.
- Cash from Investing Activities fell to -$13.2 million in Q4 2025, from -$6.1 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $23.5 million in Q3 2022 to a low of -$64.1 million in Q4 2021.
- A 5-year average of -$15.2 million and a median of -$12.5 million in 2022 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2021 — Cash from Investing Activities tumbled 581.77% — and 2022, when it jumped 168.04%.
- Tracing CRLBF's Cash from Investing Activities over 5 years: stood at -$64.1 million in 2021, then surged by 80.57% to -$12.5 million in 2022, then surged by 120.95% to $2.6 million in 2023, then sank by 215.48% to -$3.0 million in 2024, then sank by 339.5% to -$13.2 million in 2025.
- The last three Cash from Investing Activities figures came in at -$13.2 million (Q4 2025), -$6.1 million (Q3 2025), and -$3.0 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn | -491.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | -300.00 Mn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | -550.24 Mn |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn | 87.50 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -51.60 Mn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | -135.40 Mn |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn | -110.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Cresco Labs | 292.94 Mn | 228.83 Mn | 86.95 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -13.24 Mn |
| Dec 31, 2025 | -13.24 Mn |
| Sep 30, 2025 | -6.12 Mn |
| Sep 30, 2025 | -6.12 Mn |
| Dec 31, 2024 | -3.01 Mn |
| Dec 31, 2024 | -3.01 Mn |
| Sep 30, 2024 | -6.27 Mn |
| Sep 30, 2024 | -6.27 Mn |
| Dec 31, 2023 | 2.61 Mn |
| Dec 31, 2023 | 2.61 Mn |
| Sep 30, 2023 | -12.48 Mn |
| Sep 30, 2023 | -12.48 Mn |
| Dec 31, 2022 | -12.45 Mn |
| Dec 31, 2022 | -12.45 Mn |
| Sep 30, 2022 | 23.48 Mn |
| Sep 30, 2022 | 23.48 Mn |
| Dec 31, 2021 | -64.11 Mn |
| Dec 31, 2021 | -64.11 Mn |
| Sep 30, 2021 | -34.52 Mn |
| Sep 30, 2021 | -34.52 Mn |